Renaissance Capital logo

LIXT News

Micro-cap oncology biotech Lixte Biotechnology prices Nasdaq uplisting at $4.75

Lixte Biotechnology Holdings logo

Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, raised $6 million by offering 1.2 million units at $4.75, as expected. The company offered 0.3 million fewer units than expected. Each unit...read more

Micro-cap oncology biotech Lixte Biotechnology lowers deal size, now offering units in $7 million Nasdaq uplisting

Lixte Biotechnology Holdings logo

Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, lowered the proposed deal size for its upcoming Nasdaq IPO on Monday. In its latest filing, the company also changes the security type offered to...read more

Micro-cap oncology biotech Lixte Biotechnology sets terms for $9 million Nasdaq uplisting

Lixte Biotechnology Holdings logo

Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, announced terms for its IPO on Tuesday. The East Setauket, NY-based company plans to raise $9 million by offering 1.5 million shares at a...read more

US IPO Weekly Recap: The September IPO market kicks off with a quiet week

CMLFU

While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more